Third-line systemic treatment for non-small cell lung cancer

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: In patients with advanced (Stage IIIB and IV) NSCLC with EGFR wild‐type, unknown status of EGFR, or with EGFR activating mutations ( Mountain 1997 ), to assess in terms of OS and PFS the clinical efficacy of third‐line chemotherapy compared to placebo or best supportive care, third‐line targeted therapy compared to placebo or best supportive care, the third‐line combination of chemotherapy and targeted therapy compared to placebo or best supportive care; and to assess the relative efficacy of third‐line chemotherapy compared to targeted therapy.